AMRS earnings

EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President

Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th

EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh

Sixth consecutive quarter of record consumer revenue – Consumer revenue of $46.6 million increased 98% compared to Q3 2021Record core revenue of $71.1 million grew 49% compared to the prior year quarter"Fit to Win" revenue, cost and cash actions deliver $10 million in Q3$180 million of new funding closed - strategic transaction on track to self-fund growthEMERYVILLE, Calif., Nov. 8, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced financial results for the third quarter ended September 30, 202

EMERYVILLE, Calif., Nov. 1, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the third quarter ended September 30, 2022, on the afternoon of Tuesday, November 8, 2022, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo

Record consumer revenue of $43 million increased 108% compared to Q2 2021Ingredients sold out in first half with $15 million backlog to be supplied in H2Cost actions and price increases to deliver $50 million of EBITDA improvements in H2$700 million non-equity funding and earnout provides liquidity to sustained profitabilityEMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the second quarter ended June 30, 2022. "Q2 2022 Core revenue of $65.2 m

EMERYVILLE, Calif., July 28, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that it will issue its financial results for the second quarter ended June 30, 2022, on the morning of Tuesday, August 9, 2022, prior to the opening of the financial markets. The company will hold a conference call and webcast at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), during which, John Melo, President and Chief Executive Of

Record consumer revenue of $34.6 million increased 121% compared to Q1 2021Barra Bonita commissioning on track to commence ingredients production in Q2EMERYVILLE, Calif., May 10, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for the first quarter ended March 31, 2022. "We continued to advance our growth roadmap, delivering 75% core revenue growth and growing consumer revenue by 121% versus the prior year quarter to a new record of $35 million. Technology access revenue grew 33% year-over-year to $23 mill

EMERYVILLE, Calif., May 3, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that it will issue its financial results for the first quarter ended March 31, 2022, on the morning of Tuesday, May 10, 2022, prior to the opening of the financial markets. The company will hold a conference call and webcast at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), during which, John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss Amyris' financial results and provide an update on the

EMERYVILLE, Calif., March 1, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2021. "Accelerating growth of our consumer brands resulted in record levels for our consumer and core revenue," said John Melo, President and Chief Executive Officer. "Biossance and Pipette, together with better than expected performance of our recently launche

EMERYVILLE, Calif., Feb. 22, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2021, on the morning of Tuesday, March 1, 2022, prior to the opening of the financial markets. The company will hold a conference call and webcast at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), during which, John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss Amyris' financial results and provi

EMERYVILLE, Calif., Nov. 18, 2021 /PRNewswire/ -- Amyris, Inc., (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that it will host a conference call and live webcast to discuss its recent financing activity on Monday, November 22, 2021 beginning at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss the Company's recent strategic financing. Webcast: please visit http://investors.amyris.com A replay of the webcast will be archived for 90 days on this site. Live call: (

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced financial results for its third quarter ended September 30, 2021. "Amyris delivered another strong quarter along with solid strategic execution amid challenging external global supply chain conditions," said John Melo, President and Chief Executive Officer. "Once again, we realized record underlying revenue and record consumer revenue demonstrating

EMERYVILLE, Calif., Oct. 28, 2021 /PRNewswire/ -- Amyris, Inc., (NASDAQ:AMRS), a leading synthetic biotechnology company active in the Clean Health, Beauty and Wellness markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it will issue its financial results for the third quarter ended September 30, 2021 after the close of the financial markets on Monday, November 8, 2021. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President and Chief Executive Officer, Han Kieftenbeld, Chief Financial Officer, and Eduardo Alvarez, Chief Operating Officer, will

EMERYVILLE, Calif., Sept. 22, 2021 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company in the Clean Health, Beauty and Wellness markets, today announced that it will host its fourth virtual investor webinar on Tuesday, September 28, 2021. This fourth webinar titled "Lab-to-Market, Delivering Disruptive Health and Beauty Products" will be conducted via live webcast and teleconference on Tuesday, September 28, 2021 at 1:00 pm ET (10:00 am PT). Management will discuss Amyris' Lab-to-MarketTM biotechnology platform, the value proposition of its portfolio connection, the essential link between Amyris' differentiated ingredients and recently launched consumer bran

EMERYVILLE, Calif., Aug. 5, 2021 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company active in the Clean Health, Beauty and Wellness markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced financial results for its second quarter ended June 30, 2021. "With Q2 we completed another quarter of strong strategic and operational execution," said John Melo, President and Chief Executive Officer. "We delivered record underlying revenue driven by record consumer revenue while significantly improvin

EMERYVILLE, Calif., July 21, 2021 /PRNewswire/ --  Amyris, Inc., (NASDAQ:AMRS), a leading synthetic biotechnology company active in the Clean Health, Beauty and Wellness markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it will issue its financial results for the second quarter ended June 30, 2021 on the morning of Thursday, August 5, 2021, prior to the opening of the financial markets. The company will hold a conference call and webcast at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time), during which, John Melo